HEALTH TECHNOLOGY ASSESSMENT FOR TREATMENT OF CHRONIC HEPATITIS C REIMBURSED BY PUBLIC HEALTH FUND IN BULGARIA, 2016
Journal Title: Българско списание за обществено здраве (Bulgarian Journal of Public Health) - Year 2016, Vol 0, Issue 3
Abstract
In this study there have been defined the direct costs of treatment of chronic hepatitis C (CHC) by protease inhibitors (Pi), NS5B inhibitors (NS5Bi), NS5A inhibitors (NS5Ai) and calculated the coefficient of efficiency of the additional costs (incremental cost-effectiveness ratio, ICER) per year, consistent with the quality of life (quality adjusted life year, QALY) in Bulgaria through transfer and adaptation of data from evaluations of Pi, NS5Bi, NS5Ai therapies to the local environment. The aim is to create pharmacotherapy guidance for treatment of CHC based on evidence, for comparative therapeutic efficacy and cost effectiveness of medicinal alternatives as the main approach to the management of public expenditure in Bulgaria. Material and methods. There has been made a systematic review of published data from analyses of the cost-effectiveness of Pi, NS5Bi, NS5Ai to treat CHC. Databases used are: MEDLINE, EMBASE, Web of Science, Cochrane Library. Literature search covers the period from January 2014 to July 2016. Data for health benefits in terms of additional QALY are directly transferred for the purposes of this analysis. Data on direct health care costs, associated with the treatment by Pi, NS5Bi, NS5Ai, are based on local reference prices in Bulgaria by August 2016. Results. The selection of published data on the costeffectiveness of Pi, NS5Bi, NS5Ai to treat CHC, identified 12 studies included in this analysis. The summarized analysis requires the following conclusions: 1. The use of combination drug therapies that do not involve Pegylated interferon (peginterferon, pegIFN), as SOF + LED and OMB + PAR + RIT ± DAS + R, is a cost non-effective approach compared with combination therapies containing peginterferon, in the treatment of patients with CHC (GT1,4 ± CIR. 2. In an indirect comparison of combination drug therapies presented in a pharmaceutical form (OMB/ PAR/RIT vs SOF/LED), used in combinations that do not include peginterferon, found that OMB/PAR/ RIT dominates SOF/LED with a better therapeutic outcomes and lower cost for treatment cycle (ΔQALY + 0,73; Δcosts - 7516 BGN). In conclusion, pharmacotherapy guidelines for the treatment of patients with CHC GT1,4 ± CIR in Bulgaria based on a comparative assessment of therapeutic efficacy, safety and pharmaco-economic indicators recommended as first therapeutic line the use of peginterferon, including combinations and only after failure as a second therapeutic line to use combination therapies as SOF/LED and OMB/PAR/RIT.
Authors and Affiliations
Tony Vekov, Petko Salchev
Keywords
Related Articles
- EP ID EP473865
- DOI -
- Views 127
- Downloads 0
DESIGN AND METHODOLOGY OF NATIONAL SURVEY ON NUTRITION OF INFANTS AND CHILDREN UNDER 5 YEARS OF AGE AND FAMILY CHILD REARING in BULGARIA
Adequate nutrition of infants and young children is one of the factors that determine an optimal physical and psychological development and good health status. Prevention of nutritional deficiencies and nutritional statu...
CURRENT TRENDS IN SUSTAINABLE MEDICINES MARKE
Price-gouging in the health care sector has attracted serious public attention and has become highly politicized in many jurisdictions. The ongoing EU Commission‘s probe into excessive pricing practices suggests that, at...
ROLE OF THE AUDIENCE SEGMENTATION FOR THE HEALTH COMMUNICATION PROCESS
Health communication is a multifaceted and multidisciplinary approach to sharing health information and is an integral part of the programs of health promotion. Good knowledge of the audience allows the health message an...
CHARACTERISTICS AND TRENDS IN HEALTH DEMOGRAPHIC PROCESSES IN BULGARIA FOR THE PERIOD 1880-2012
Extremely interesting historical data on the demographic processes of Liberation are summarized and suggested. An analysis has been done and trends in population movement - natural and mechanical have been established. B...
LIVER RESECTION FOR NON-COLORECTAL NONNEUROENDOCRINE LIVER METASTASES
Background/Aims: resection of colorectal liver metastases has become the standard, but value for non- colorectal non- neuroendocrine liver metastases (NCRNNLM) remains controversial. The purpose of this study is to asses...